ReNeuron Group plc Block Listing Review & Total Voting Rights (7044K)

TIDMRENE

RNS Number : 7044K

ReNeuron Group plc

01 September 2023

ReNeuron Group plc

("ReNeuron" or the "Company")

Block Listing Review

and Total Voting Rights

ReNeuron Group plc (AIM: RENE) , a UK-based leader in stem cell derived exosome technologies, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.

 
 Name:                               ReNeuron Group plc 
 Name of Scheme:                     ReNeuron Share Option Schemes 
                                    --------------------------------------- 
 Period of Return:                   From 1 March 2023 to 31 August 2023 
                                    --------------------------------------- 
 Balance of unallotted securities    3,345,632 Ordinary Shares (of 1p each) 
  under scheme(s) from previous 
  return: 
                                    --------------------------------------- 
 Plus : The amount by which 
  the block scheme(s) has been 
  increased since the date 
  of the last Review (if any 
  increase has been applied 
  for):                              5,254,368 
                                    --------------------------------------- 
 Less : Number of securities         - 
  issued/allotted under scheme(s) 
  during period 
                                    --------------------------------------- 
 Equals : Balance under scheme(s)    8,600,000 Ordinary Shares 
  not yet issued/allotted at 
  end of period: 
                                    --------------------------------------- 
 Number and class of securities      20,000 ordinary shares on 13 May 2010 
  originally admitted and the 
  date of admission: 
                                    --------------------------------------- 
 

Total Voting Rights

At 31 August 2023, the Company had 57,173,760 Ordinary Shares in issue, each carrying one voting right.

As the Company holds no ordinary shares in treasury, the figure of 57,173,760 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

ENDS

Contacts:

 
 
   ReNeuron                                                              www.reneuron.com/investors 
 Iain Ross, Executive Chairman                                                      Via Walbrook PR 
 John Hawkins, Chief Financial Officer 
 
 Allenby Capital Limited (Nominated 
  Adviser and Broker)                                                           [phone] 
 James Reeve/George Payne/Dan Dearden-Williams 
  (Corporate Finance) 
 Stefano Aquilino/Kelly Gardiner 
  (Sales & Corporate Broking) 
 
 Walbrook PR (Media & Investor Relations)            [phone] or [e-mail] 
 Paul McManus / Alice Woodings                                [phone] / [phone] 
                                                                                                654 
 
 

About ReNeuron

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.

Through the generation of several unique and scalable exosome producer cell lines, our CustomEX(TM) platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRPLMITMTITBFJ

(END) Dow Jones Newswires

September 01, 2023 02:00 ET (06:00 GMT)